Question 1

What has glutathione actually been compared against?

Accepted Answer

Almost always a dummy capsule. Every randomised human trial behind this page set glutathione against placebo, which answers whether it does more than nothing and leaves open whether it does more than anything else. The design is consistent across very different groups. In one trial, children with cystic fibrosis received reduced glutathione or placebo orally daily, and at the end no significant differences were seen between glutathione (n = 30) and placebo (n = 28) groups in the 6-month change in weight-for-age z-score, a standard growth measure. Obese men with and without diabetes were randomised in a double-blinded placebo-controlled manner, as were adults in the six-month body-stores trial and people with acne. Animal work follows the same pattern with a different dummy. In a fat-grafting experiment, human fat was placed under the skin of normal saline-treated (control) or GSH-treated nude mice, saline being salt water. A placebo-controlled record is the right foundation, and it is not a comparison with a rival. For that, the sections below look at what has been set side by side, and what has not.

Question 2

How does glutathione compare with NAC?

Accepted Answer

NAC, short for N-acetylcysteine, is not a rival compound so much as a different route to the same place. It supplies cysteine, the raw material the body uses to build its own glutathione, so taking NAC asks the body to make more while taking glutathione supplies the finished molecule. The reviews treat the two as one strategy. A 2026 review of HIV and tuberculosis describes glutathione repletion, achieved through direct supplementation or precursor approaches such as N-acetylcysteine, Glycine and N-acetylcysteine (GlyNAC), and cysteine-rich dietary interventions. GlyNAC is NAC paired with the amino acid glycine. The nearest thing to a side-by-side comes from one 2022 study, which used both, in different models. In pregnant mice exposed to plastic particles, NAC alleviated PS particles-induced oxidative injury in the fetal brain. In nerve cells grown in a dish, the same damage was prevented by glutathione supplementation. That is two compounds working in two settings, rather than one contest, and no human trial among these sources has given NAC to one group and glutathione to another.

Question 3

What does NAC do to glutathione in animals?

Accepted Answer

It raises it, and that is the whole reason NAC sits next to glutathione in this work. Two animal studies show it doing that job in two different places in the body. In rats, NAC given before the hearts were studied raised their glutathione, and the authors drew a conclusion about glutathione rather than about NAC: glutathione supplementation may therefore provide therapeutic benefits for vulnerable hearts. In a dish of cultured brain cells, glutathione supplementation by the addition of its precursor N-acetyl-cysteine resulted in an increase in neuronal survival, so the researchers counted NAC as a way of supplementing glutathione. That habit of wording is worth noticing. Some papers say glutathione supplementation when what they gave was NAC, so a search for glutathione evidence turns up NAC work filed under the same name. For a reader weighing a glutathione capsule against an NAC capsule, the point is this: the animal evidence for raising glutathione in tissue sits mostly with NAC, while the human evidence for raising it in blood sits with glutathione itself.

Question 4

Is glutathione the same as glutamine?

Accepted Answer

No, though the names invite the mix-up, and one experiment put them side by side. Glutamine is a single amino acid, while glutathione is built from three. A germ in the stomach can break glutathione down, and H. suis can also convert glutathione (GSH) to glutamate, which is how the two end up in the same research on stomach infection. That overlap produced a genuine head-to-head in gerbils infected with a stomach bacterium. Oral supplementation with Gln was shown to temper H. suis induced gastritis and epithelial (hyper)proliferation in Mongolian gerbils, Gln being glutamine. Glutathione did more in the same experiment: supplementation of the feed with GSH resulted in inflammation and epithelial proliferation levels returning to baseline levels of uninfected controls. So in that animal model glutathione did better than glutamine, bringing the stomach lining back to the state of animals that were never infected, where glutamine only eased the damage. It is one experiment in one rodent with one infection, and it does not tell a reader how the two compare for anything else.

Question 5

Reduced or oxidised glutathione: which form did the studies use?

Accepted Answer

The human trials used the reduced form, which is the active one, and the oxidised form turns up mainly as something to measure. The oxidised form, called glutathione disulfide or GSSG, is what the active form turns into once it has used itself up on a damaging molecule. The children's trial names its material directly: patients received reduced glutathione or placebo. The three-week insulin trial measured both forms in muscle, and found that no change was seen in GSH to glutathione disulfide ratio, so the balance between the active and spent forms stayed put even as total muscle glutathione edged up. The oxidised form was given deliberately in one setting. Researchers added it to intravenous feeding solutions for premature babies and found that GSSG reacts with cysteine to form cysteine-glutathione mixed disulfide, another suitable glutathione substrate for preterm neonates. For a buyer, the comparison is simple at the level of a label: the trial evidence belongs to reduced glutathione, and a product that does not say which form it contains is not describing the material those trials tested.

Question 6

Oral, topical or intravenous: how does the glutathione evidence compare?

Accepted Answer

The three routes have been compared in one place only, a 2025 narrative review of skin lightening, and it compares them by summarising separate studies rather than by testing them against each other. On that reading the trade-offs run in different directions. Swallowed glutathione produced significant but variable decreases in melanin levels with limited side effects. Topical formulations provide good-level melanin reduction and skin texture improvement but with varying sustainability, meaning the change does not always hold. The drip is described as having rapid action alongside the most serious documented concerns. A route that works quickly is not the same as a route with a better record, and the review ranks none of them as best. The weight of human evidence is also uneven. The randomised trials with stated amounts are all oral, and the topical and intravenous findings rest on the review's summary of studies whose sizes are not given in its abstract. The harm side of the drip, which is where the routes differ most, is set out on the Glutathione safety page.

Question 7

Liposomal or plain glutathione: has anyone compared them?

Accepted Answer

No study among the research behind this page has given liposomal glutathione to one group and plain glutathione to another. Each form has its own evidence, and the two kinds sit in different species. Plain oral glutathione holds the human result. Before the six-month trial, its authors noted that while oral GSH has been shown to be bioavailable in laboratory animal models, its efficacy in humans has not been established, and their trial then recorded higher stores in people taking ordinary capsules. That undercuts the common claim that plain glutathione is simply destroyed in the gut. Liposomal glutathione holds the animal results. An earlier mouse study, cited in a 2023 paper, found that it could lower oxidative stress, enhance a granulomatous response, and reduce the burden of M. tb in the lungs of M. tb-infected mice, a granuloma being the immune wall built around tuberculosis. A 2026 diabetes review lists exploring targeted delivery systems as future work. So the case for liposomal superiority is an argument from design rather than a measured result, and the comparison that would settle it has not been run.

Question 8

Glutathione with vitamin C: what does the combination show?

Accepted Answer

Mostly a gap. A 2023 review set out to look at vitamin C, glutathione and the two together for exercise, and found the record for each one unsettled before it even got to the pair. On vitamin C alone, the review reports that the effects of vitamin C supplementation on exercise performance and oxidative stress levels are inconsistent. On glutathione alone, it finds mixed results across different forms and ways of taking it. The chemistry gives a reason to pair them, since vitamin C and glutathione have deeply interconnected antioxidant functions and are mutually essential to each other, which means each helps regenerate the other inside cells. The review's conclusion is careful: although an additive effect is anticipated with the combined intake of vitamin C and glutathione, research on this topic is currently insufficient, and further studies are required. Anticipated is the key word. A stack built on that pairing rests on a reason drawn from chemistry rather than on a result measured in people who train.

Question 9

Glutathione with citrulline: what can the three-arm trial separate?

Accepted Answer

It can separate citrulline alone from citrulline plus glutathione, and that is all. The 2023 trial in 44 healthy postmenopausal women had three arms: citrulline, the combination, and placebo. The comparison between the two active arms is the informative part. In this trial, citrulline alone did something to a blood marker without moving the artery: although CIT increased ARG/ADMA, it did not improve FMD in healthy PMW, where FMD is how far an artery widens when blood flow rises. The combination arm of the trial did move it, since CIT+GSH improved FMD and attenuated systolic BP and MAP reactivity in PMW, MAP being mean arterial pressure during a cold-water stress test. Read the design closely. Because no arm received glutathione on its own, the trial cannot say whether glutathione alone would have done the same, or whether the effect needs both. The fair summary is that adding glutathione to citrulline changed the result in these women, which is a finding about a pair rather than a ranking of two compounds.

Question 10

Does glutathione compare well with switching on the body's own defences?

Accepted Answer

In one mouse study, the body's own defences did better. The work looked at liver injury from a painkiller overdose and tested two ways of relieving the oxidative stress behind it. The authors report that oxidative stress relief, by glutathione supplementation and especially Nrf2 activation, resolved cuproptosis and decreased copper accumulation in the injured mouse liver. Nrf2 is a switch inside cells that turns on their own antioxidant machinery, and cuproptosis is a form of cell death driven by excess copper. Both approaches helped; the word especially puts Nrf2 activation ahead. Their closing line keeps that ranking, pointing to Nrf2 activation-mediated oxidative stress relief, which would be a promising antidote in drug-induced liver injury. That is one injury model in one species, and it does not tell a reader that any product sold as an Nrf2 activator beats a glutathione capsule. It does show that adding the finished molecule and prompting cells to make their own are not interchangeable.

Question 11

How do glutathione results compare across conditions?

Accepted Answer

They split sharply, and that is the most useful comparison on this page. The same compound, taken the same way by mouth, gave a clear result in one group and nothing in another. In obese men with and without diabetes, oral GSH supplementation improves insulin sensitivity in obese subjects with and without T2DM, although it does not alter markers of oxidative stress in that trial. In children with cystic fibrosis, oral glutathione supplementation did not impact growth over six months against placebo. In acne, oral glutathione supplementation demonstrated a non-significant trend toward reducing oxidative and nitrosative stress markers, which points one way without a confirmed effect. A 2024 review of HIV-related brain disorders draws the general lesson, writing that the potential effects of glutathione supplementation in patients with HAND are likely to differ based on the specific HIV-associated neurocognitive disease. A result in one condition does not carry over to the next. Anyone weighing glutathione against something else has to name the condition first, because the evidence for glutathione itself shifts from one to the next.

Question 12

Is glutathione better than other skin-lightening agents?

Accepted Answer

No study among the research behind this page tested glutathione against another lightening agent in the same people. The comparison exists only as a framing in the 2025 review, which describes glutathione as a potentially safer alternative to conventional agents. That sentence is the review's account of why demand rose, and it is not a measured comparison. The review gives no head-to-head figures, names no comparator in its abstract, and ends by asking for rigorous, large-scale clinical trials to establish long-term safety, optimal dosing, and standardized applications. The intravenous route, which is often the one people mean when they ask, is the route that same review ties to the most serious concerns. So potentially safer describes a hope that pushed glutathione into the market, while the trials that would test it against an established agent are still missing. A chart that ranks glutathione above another lightening agent is relying on that framing rather than on a measured comparison among the published studies behind this page.

Question 13

What would a fair glutathione comparison need?

Accepted Answer

Two products, the same people, the same outcome and enough time, and the reviews spell out the missing pieces. A 2026 review of diabetes research says that standardization of biomarkers, dose-response mapping, and long-term outcomes are urgently needed before the field can move on. The HIV and tuberculosis review asks for the same structure from the other direction: future research should prioritize rigorously designed trials incorporating mechanistic endpoints, standardized redox measurements, and clinically meaningful outcomes. Redox measurements are readings of the balance between oxidising and protective molecules, and standardised means every trial would read them the same way. Until that exists, every comparison involving glutathione is built from separate studies with different groups, amounts and endpoints, set side by side after the fact. That can suggest a direction, as the gerbil and liver experiments do. It cannot rank glutathione against NAC, a liposome, vitamin C or a lightening cream, because none of those contests has been run in people among the research behind this page. The amounts each trial used are listed on the Glutathione dosage page.

Glutathione comparisons and stacks